NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health today provides an update on progress towards the completion of the
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
Brent crude oil traded at $85 per barrel on Thursday, nearing two-month highs. This was buoyed in part by the expectation that a strong economic recovery would boost demand. However,
Analysts predict that oil prices will rise further this year after rising 50% in 2021. They believe that a shortage of production capacity and low investment could cause crude to
Due to tight supply and decreasing concerns about potential demand from the Omicron coronavirus variant, oil prices reached two-month highs Wednesday.
Oil prices rose to above $78 per barrel Monday. This was due to tight supply and the hopes of a further demand recovery by 2022.